FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394501> ?p ?o ?g. }

• W4308394501 abstract "<h3>Background</h3> HER2 is a well-established therapeutic target that is overexpressed in multiple cancers. Monoclonal antibodies (mAbs) targeting HER2 such as Herceptin (trastuzumab) and Perjeta (pertuzumab) have been used in the clinic for many years. Despite good outcomes, there remains an unmet medical need that requires the further development of novel agents for recurrent or metastatic patients. The combination of HER2 mAbs have shown synergistic activity with improved clinical benefit. Moreover, biparatopic antibodies that are composed of trastuzumab and pertuzumab binding domains have shown promising results in the clinic. 4-1BB is a potent stimulator of T cells and NK cells, and when activated, can improve effector and/or memory responses. However, inherent hepatotoxicity has been observed during the clinical development of 4-1BB agonists. PM1234 is a trispecific antibody that binds to two different epitopes of HER2 (ECD4 and ECD2), and the CRD4 domain of 4-1BB. PM1234 stimulates immune cells such as T cells via HER2-mediated cross-bridging and 4-1BB activation, which results in potent anti-tumor efficacy. Moreover, Fc-effector function was shown to be essential for the <i>in vivo</i> anti-tumor efficacy of PM1234. <h3>Methods</h3> PM1234 was generated as a biparatopic heterodimeric (1+1) IgG-like antibody composed of both trastuzumab and pertuzumab binding domains with anti-4-1BB VHHs fused to the C-terminus of the Fc. The immunomodulatory functions of PM1234 were evaluated using luciferase reporter cell assays, PBMC/primary T cell activation assays, and human 4-1BB KI mouse tumor models. <h3>Results</h3> PM1234 displayed strong HER2 binding and signal inhibition activity due to its biparatopic binding nature. The binding mode of PM1234 may allow up to double the available HER2 binding domains that can facilitate 4-1BB crosslinking and activation and was thus more potent than non-biparatopic anti-HER2 x 4-1BB bispecifics (trastuzumab x 4-1BB and/or pertuzumab x 4-1BB). PM1234 retained Fc effector function towards HER2 but with negligible activity towards the 4-1BB-targeting arm. PM1234 showed more potent activity in <i>in vivo</i> CT26 and MC38 tumor models than the control molecules containing Fc-silencing mutations, the combination of trastuzumab and pertuzumab, and anti-HER2-ADC. Importantly, PM1234 induced immune memory and potent anti-tumor efficacy to both HER2+ primary tumors and distal tumors without HER2 expression. <h3>Conclusions</h3> PM1234 exhibited potent anti-tumor activity with the induction of strong immunological memory to suppress both primary HER2+ tumors and distal tumors. The differentiation of PM1234 shows the next-generation potential of HER2-targeted therapies in this competitive space and provides an insight into further improvements for benefiting patients with HER2+ tumors. <h3>Ethics Approval</h3> All mice were maintained under specified pathogen-free conditions, and all studies were approved by the Animal Care and Use Committee of HUST-Suzhou Institute for Brainsmatics." @default.
• W4308394501 created "2022-11-11" @default.
• W4308394501 creator A5017096532 @default.
• W4308394501 creator A5017753879 @default.
• W4308394501 creator A5024748774 @default.
• W4308394501 creator A5052910922 @default.
• W4308394501 creator A5055838753 @default.
• W4308394501 creator A5057282533 @default.
• W4308394501 creator A5057765611 @default.
• W4308394501 creator A5084511556 @default.
• W4308394501 creator A5088616270 @default.
• W4308394501 date "2022-11-01" @default.
• W4308394501 modified "2023-09-24" @default.
• W4308394501 title "1321 A biparatopic anti-HER2 antibody enabled with conditional 4–1BB agonism induces potent anti-tumor efficacy" @default.
• W4308394501 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1321" @default.
• W4308394501 hasPublicationYear "2022" @default.
• W4308394501 type Work @default.
• W4308394501 citedByCount "0" @default.
• W4308394501 crossrefType "proceedings-article" @default.
• W4308394501 hasAuthorship W4308394501A5017096532 @default.
• W4308394501 hasAuthorship W4308394501A5017753879 @default.
• W4308394501 hasAuthorship W4308394501A5024748774 @default.
• W4308394501 hasAuthorship W4308394501A5052910922 @default.
• W4308394501 hasAuthorship W4308394501A5055838753 @default.
• W4308394501 hasAuthorship W4308394501A5057282533 @default.
• W4308394501 hasAuthorship W4308394501A5057765611 @default.
• W4308394501 hasAuthorship W4308394501A5084511556 @default.
• W4308394501 hasAuthorship W4308394501A5088616270 @default.
• W4308394501 hasBestOaLocation W43083945011 @default.
• W4308394501 hasConcept C121608353 @default.
• W4308394501 hasConcept C126322002 @default.
• W4308394501 hasConcept C159654299 @default.
• W4308394501 hasConcept C185592680 @default.
• W4308394501 hasConcept C195616568 @default.
• W4308394501 hasConcept C203014093 @default.
• W4308394501 hasConcept C2776090121 @default.
• W4308394501 hasConcept C2779786085 @default.
• W4308394501 hasConcept C2781164504 @default.
• W4308394501 hasConcept C40677261 @default.
• W4308394501 hasConcept C502942594 @default.
• W4308394501 hasConcept C51785407 @default.
• W4308394501 hasConcept C530470458 @default.
• W4308394501 hasConcept C542903549 @default.
• W4308394501 hasConcept C71924100 @default.
• W4308394501 hasConcept C8891405 @default.
• W4308394501 hasConcept C98274493 @default.
• W4308394501 hasConceptScore W4308394501C121608353 @default.
• W4308394501 hasConceptScore W4308394501C126322002 @default.
• W4308394501 hasConceptScore W4308394501C159654299 @default.
• W4308394501 hasConceptScore W4308394501C185592680 @default.
• W4308394501 hasConceptScore W4308394501C195616568 @default.
• W4308394501 hasConceptScore W4308394501C203014093 @default.
• W4308394501 hasConceptScore W4308394501C2776090121 @default.
• W4308394501 hasConceptScore W4308394501C2779786085 @default.
• W4308394501 hasConceptScore W4308394501C2781164504 @default.
• W4308394501 hasConceptScore W4308394501C40677261 @default.
• W4308394501 hasConceptScore W4308394501C502942594 @default.
• W4308394501 hasConceptScore W4308394501C51785407 @default.
• W4308394501 hasConceptScore W4308394501C530470458 @default.
• W4308394501 hasConceptScore W4308394501C542903549 @default.
• W4308394501 hasConceptScore W4308394501C71924100 @default.
• W4308394501 hasConceptScore W4308394501C8891405 @default.
• W4308394501 hasConceptScore W4308394501C98274493 @default.
• W4308394501 hasLocation W43083945011 @default.
• W4308394501 hasOpenAccess W4308394501 @default.
• W4308394501 hasPrimaryLocation W43083945011 @default.
• W4308394501 hasRelatedWork W2019405644 @default.
• W4308394501 hasRelatedWork W2028537611 @default.
• W4308394501 hasRelatedWork W2042242992 @default.
• W4308394501 hasRelatedWork W2460150844 @default.
• W4308394501 hasRelatedWork W2480895977 @default.
• W4308394501 hasRelatedWork W2547014277 @default.
• W4308394501 hasRelatedWork W2773030148 @default.
• W4308394501 hasRelatedWork W28762221 @default.
• W4308394501 hasRelatedWork W2886978921 @default.
• W4308394501 hasRelatedWork W3195831375 @default.
• W4308394501 isParatext "false" @default.
• W4308394501 isRetracted "false" @default.
• W4308394501 workType "article" @default.